The completion of three recent clinical trials, two of which specifically examined MK-0646 and MK-8669, reinforce the added value of targeting IGF-1R in conjunction with mTOR in advanced hormone receptor-positive breast cancer tumors. This evidence concerns the gene IGF1R and breast carcinoma.